Earlier studies from our group have revealed the ability of PB (5-hydroxy-2-methyl-1, 4-naphthoquinone) to selectively target BRCA1-defective ovarian cancer cells [21–24] as well as BRCA1-knockout breast cancer xenografts (unpublished data). This evidence concerns the gene BRCA1 and ovarian cancer.